Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2019 to Oct 2024
Affymetrix Provides Aventis Pharmaceuticals Early Access to High-Throughput
GeneChip(R) Platform
SANTA CLARA, Calif., March 3 /PRNewswire-FirstCall/ -- Affymetrix, Inc., today
announced that Aventis Pharmaceuticals has entered into an agreement that
provides Aventis early access to the new GeneChip(R) HighThroughputArray (HTA)
that uses a standard 96-well microtiter plate footprint to simultaneously
process and analyze 96 GeneChip Human Genome U133A Arrays.
"The GeneChip HTA system industrializes the workflow of processing
microarray-based experiments, creating a new price/performance point in the
industry," said Steve Lombardi, Vice President of Corporate Development at
Affymetrix. "HTA will enable pharmaceutical companies to implement and apply
GeneChip technology in high-throughput drug development applications through its
reliability and lowered cost per experiment."
The GeneChip HTA system has the capacity to process hundreds of biological
samples per day with minimal human supervision, reducing capital, labor,
reagent, and array expenses. The GeneChip HTA system adapts the same industry-
standard GeneChip brand technology and content that Affymetrix uses in its
cartridges to a standard 96-array format, which runs on an automated system
built with off-the-shelf robotic components. The GeneChip HTA system automates
the most labor intensive steps in GeneChip processing, dramatically reducing the
cost per assay. The decrease in cost and increase in throughput enables
industrialized genomics-based research and makes the GeneChip HTA system well
suited for downstream development applications like compound profiling,
toxicology and clinical trials.
The components of the GeneChip HTA system include the HTA 96-array plate, a new
scanner for analyzing the HTA plates, the automated assay adapted from
Affymetrix' standard gene expression assay, specifications for the automation
components, and a software system for tracking samples and data. Further
development on the system will enable high-throughput studies employing other
products and applications, including genotyping, resequencing and chromatin
immunoprecipitation.
About Affymetrix:
Affymetrix is a pioneer in creating breakthrough tools that are driving the
genomic revolution. By applying the principles of semiconductor technology to
the life sciences, Affymetrix develops and commercializes systems that enable
scientists to improve quality of life. The Company's customers include
pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products
companies as well as academic, government and other non- profit research
institutes. Affymetrix offers an expanding portfolio of integrated products and
services, including its integrated GeneChip platform, to address growing markets
focused on understanding the relationship between genes and human health.
Additional information on Affymetrix can be found at
http://www.affymetrix.com/.
All statements in this press release that are not historical are "forward-
looking statements" within the meaning of Section 21E of the Securities Exchange
Act as amended, including statements regarding Affymetrix' "expectations,"
"beliefs," "hopes," "intentions," "strategies" or the like. Such statements are
subject to risks and uncertainties that could cause actual results to differ
materially for Affymetrix from those projected, including, but not limited to
risks of the Company's ability to achieve and sustain higher levels of revenue,
higher gross margins, reduced operating expenses, uncertainties relating to
technological approaches, manufacturing, product development, market acceptance
(including uncertainties relating to product development and market acceptance
of the GeneChip HighThroughputArray format), personnel retention, uncertainties
related to cost and pricing of Affymetrix products, dependence on collaborative
partners, uncertainties relating to sole source suppliers, uncertainties
relating to FDA and other regulatory approvals, competition, risks relatingto
intellectual property of others and the uncertainties of patent protection and
litigation. These and other risk factors are discussed in Affymetrix' Form 10-K
for the year ended December 31, 2002 and other SEC reports, including its
Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward- looking statements contained herein to
reflect any change in Affymetrix' expectations with regard thereto or any change
in events, conditions, or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks
owned or used by Affymetrix, Inc.
DATASOURCE: Affymetrix, Inc.
CONTACT: Media Contact: Wes Conard, Associate Director, Public
Relations, +1-408-731-5791, or Investor Contact: Doug Farrell, Vice President,
Investor Relations, +1-408-731-5285, both of Affymetrix, Inc.
Web site: http://www.affymetrix.com/